Mitchell S V Elkind1, Jorge M Luna, Leslie A McClure, Yu Zhang, Christopher S Coffey, Ana Roldan, Oscar H Del Brutto, Edwin Javier Pretell, L Creed Pettigrew, Brett C Meyer, Jorge Tapia, Carole White, Oscar R Benavente. 1. From the Department of Neurology, College of Physicians and Surgeons (M.S.V.E., J.M.L.), Department of Epidemiology, Mailman School of Public Health (M.S.V.E., J.M.L.), and Gertrude H. Sergievsky Center (M.S.V.E.), Columbia University, New York, NY; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL (L.A.M., Y.Z.); Department of Biostatistics, University of Iowa, Iowa City, IA (C.S.C.); Department of Neurology, University of Texas at Houston, Houston, TX (A.R.); School of Medicine, Universidad Espíritu Santo-Ecuador, Guayaquil, Ecuador (O.H.D.B.); Department of Neurology, Hospital Alberto Sabogal, Lima, Peru (E.J.P.); Department of Neurology, University of Kentucky, Lexington, KY (L.C.P.); Department of Neurology, University of San Diego, San Diego, CA (B.C.M.); Department of Neurology, Pontificia Universidad Católica de Chile, Santiago, Chile (J.T.); School of Nursing and Secondary Prevention of Small Subcortical Strokes (SPS3) Coordinating Center, University of Texas Health Science Center at San Antonio, San Antonio, TX (C.W.); and Department of Medicine, Division of Neurology, University of British Columbia, Vancouver, BC, Canada (O.R.B.).
Abstract
BACKGROUND AND PURPOSE: Inflammatory biomarkers predict incident and recurrent cardiac events, but their relationship to stroke prognosis is uncertain. We hypothesized that high-sensitivity C-reactive protein (hsCRP) predicts recurrent ischemic stroke after recent lacunar stroke. METHODS:Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) was an international, multicenter, prospective ancillary biomarker study nested within Secondary Prevention of Small Subcortical Strokes (SPS3), a phase III trial in patients with recent lacunar stroke. Patients were assigned in factorial design to aspirin versus aspirin plus clopidogrel, and higher versus lower blood pressure targets. Patients had blood samples collected at enrollment and hsCRP measured using nephelometry at a central laboratory. Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for recurrence risks before and after adjusting for demographics, comorbidities, and statin use. RESULTS: Among 1244 patients with lacunar stroke (mean age, 63.3±10.8 years), median hsCRP was 2.16 mg/L. There were 83 recurrent ischemic strokes (including 45 lacunes) and 115 major vascular events (stroke, myocardial infarction, and vascular death). Compared with the bottom quartile, those in the top quartile (hsCRP>4.86 mg/L) were at increased risk of recurrent ischemic stroke (unadjusted HR, 2.54; 95% CI, 1.30-4.96), even after adjusting for demographics and risk factors (adjusted HR, 2.32; 95% CI, 1.15-4.68). hsCRP predicted increased risk of major vascular events (top quartile adjusted HR, 2.04; 95% CI, 1.14-3.67). There was no interaction with randomized antiplatelet treatment. CONCLUSIONS: Among recent lacunar stroke patients, hsCRP levels predict the risk of recurrent strokes and other vascular events. hsCRP did not predict the response to dual antiplatelets. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00059306.
RCT Entities:
BACKGROUND AND PURPOSE: Inflammatory biomarkers predict incident and recurrent cardiac events, but their relationship to stroke prognosis is uncertain. We hypothesized that high-sensitivity C-reactive protein (hsCRP) predicts recurrent ischemic stroke after recent lacunar stroke. METHODS: Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) was an international, multicenter, prospective ancillary biomarker study nested within Secondary Prevention of Small Subcortical Strokes (SPS3), a phase III trial in patients with recent lacunar stroke. Patients were assigned in factorial design to aspirin versus aspirin plus clopidogrel, and higher versus lower blood pressure targets. Patients had blood samples collected at enrollment and hsCRP measured using nephelometry at a central laboratory. Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for recurrence risks before and after adjusting for demographics, comorbidities, and statin use. RESULTS: Among 1244 patients with lacunar stroke (mean age, 63.3±10.8 years), median hsCRP was 2.16 mg/L. There were 83 recurrent ischemic strokes (including 45 lacunes) and 115 major vascular events (stroke, myocardial infarction, and vascular death). Compared with the bottom quartile, those in the top quartile (hsCRP>4.86 mg/L) were at increased risk of recurrent ischemic stroke (unadjusted HR, 2.54; 95% CI, 1.30-4.96), even after adjusting for demographics and risk factors (adjusted HR, 2.32; 95% CI, 1.15-4.68). hsCRP predicted increased risk of major vascular events (top quartile adjusted HR, 2.04; 95% CI, 1.14-3.67). There was no interaction with randomized antiplatelet treatment. CONCLUSIONS: Among recent lacunar strokepatients, hsCRP levels predict the risk of recurrent strokes and other vascular events. hsCRP did not predict the response to dual antiplatelets. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00059306.
Authors: M S V Elkind; J M Luna; C S Coffey; L A McClure; K M Liu; S Spitalnik; M C Paik; A Roldan; C White; R Hart; O Benavente Journal: Int J Stroke Date: 2010-04 Impact factor: 5.266
Authors: Salvador Cruz-Flores; Alejandro Rabinstein; Jose Biller; Mitchell S V Elkind; Patrick Griffith; Philip B Gorelick; George Howard; Enrique C Leira; Lewis B Morgenstern; Bruce Ovbiagele; Eric Peterson; Wayne Rosamond; Brian Trimble; Amy L Valderrama Journal: Stroke Date: 2011-05-26 Impact factor: 7.914
Authors: Oscar R Benavente; Robert G Hart; Leslie A McClure; Jeffrey M Szychowski; Christopher S Coffey; Lesly A Pearce Journal: N Engl J Med Date: 2012-08-30 Impact factor: 91.245
Authors: A Chamorro; R L Sacco; J P Mohr; M A Foulkes; C S Kase; T K Tatemichi; P A Wolf; T R Price; D B Hier Journal: Stroke Date: 1991-02 Impact factor: 7.914
Authors: Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245
Authors: Clinton B Wright; Myunghee C Paik; Truman R Brown; Sally P Stabler; Robert H Allen; Ralph L Sacco; Charles DeCarli Journal: Stroke Date: 2005-05-05 Impact factor: 7.914
Authors: Juan F Arenillas; José Alvarez-Sabín; Carlos A Molina; Pilar Chacón; Joan Montaner; Alex Rovira; Bernardo Ibarra; Manuel Quintana Journal: Stroke Date: 2003-09-18 Impact factor: 7.914
Authors: Anna Maria Gori; Betti Giusti; Benedetta Piccardi; Patrizia Nencini; Vanessa Palumbo; Mascia Nesi; Antonia Nucera; Giovanni Pracucci; Paolina Tonelli; Eleonora Innocenti; Alice Sereni; Elena Sticchi; Danilo Toni; Paolo Bovi; Mario Guidotti; Maria Rosaria Tola; Domenico Consoli; Giuseppe Micieli; Rossana Tassi; Giovanni Orlandi; Maria Sessa; Francesco Perini; Maria Luisa Delodovici; Maria Luisa Zedde; Francesca Massaro; Rosanna Abbate; Domenico Inzitari Journal: J Cereb Blood Flow Metab Date: 2017-03-07 Impact factor: 6.200
Authors: A Nouvenne; A Ticinesi; F Lauretani; M Maggio; G Lippi; B Prati; L Borghi; T Meschi Journal: J Nutr Health Aging Date: 2016-04 Impact factor: 4.075
Authors: Amelia K Boehme; Leslie A McClure; Yu Zhang; Jorge M Luna; Oscar H Del Brutto; Oscar R Benavente; Mitchell S V Elkind Journal: Stroke Date: 2016-03 Impact factor: 7.914
Authors: J J McCabe; E O'Reilly; S Coveney; R Collins; L Healy; J McManus; R Mulcahy; B Moynihan; T Cassidy; F Hsu; B Worrall; S Murphy; M O'Donnell; P J Kelly Journal: Eur Stroke J Date: 2021-01-05
Authors: Helen C Segal; Annette I Burgess; Debbie L Poole; Ziyah Mehta; Louise E Silver; Peter M Rothwell Journal: Stroke Date: 2014-08-26 Impact factor: 7.914
Authors: Natalia S Rost; James F Meschia; Rebecca Gottesman; Lisa Wruck; Karl Helmer; Steven M Greenberg Journal: Stroke Date: 2021-05-27 Impact factor: 10.170